DiaMedica Therapeutics
DMAC
58 hedge funds and large institutions have $34.2M invested in DiaMedica Therapeutics in 2025 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 19 increasing their positions, 5 reducing their positions, and 20 closing their positions.
700% more call options, than puts
Call options by funds: $8K | Put options by funds: $1K
280% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 5
20% more capital invested
Capital invested by funds: $28.5M → $34.2M (+$5.7M)
2.91% more ownership
Funds ownership: 17.53% → 20.44% (+2.9%)
2% more funds holding
Funds holding: 57 → 58 (+1)
5% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 20
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$4.23M |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.23M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$716K |
| 4 |
State Street
Boston,
Massachusetts
|
+$651K |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$574K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$2.04M |
| 2 |
Millennium Management
New York
|
-$1.28M |
| 3 |
Goldman Sachs
New York
|
-$405K |
| 4 |
Jane Street
New York
|
-$382K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$304K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TRCT
76
Tower Research Capital (TRC)
New York
| – | -$2.8K | -738 | Closed |
|
|
PD
77
Point72 (DIFC)
Dubai,
United Arab Emirates
| – | -$2.43K | -642 | Closed |
|
78
Simplex Trading
Chicago,
Illinois
| – | -$1.46K | -374 | Closed |
|
DMAC Hedge Fund Activity: Q2 2025 in Review
58 of the 7,598 institutional investors tracked by Wall St. Rank reported a position in DiaMedica Therapeutics (DMAC) for Q2 2025, worth a combined $34.2M — up 20% from $28.5M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new DMAC positions and 20 closed out — a net gain of 1 holder — while 19 added to existing stakes and 5 trimmed.
The largest buyer was BlackRock, adding an estimated $4.23M. The largest seller was Susquehanna International Group, cutting an estimated $2.04M.
- 58 institutional investors held DiaMedica Therapeutics (DMAC) as of Q2 2025, up from 57 in Q1 2025.
- Funds reported $34.2M of DiaMedica Therapeutics stock for Q2 2025, up 20% quarter-over-quarter.
- 21 funds opened new DiaMedica Therapeutics positions in Q2 2025 and 20 closed out, a net change of +1 holder.
- The largest DiaMedica Therapeutics buyer in Q2 2025 was BlackRock, an estimated $4.23M added.
- The largest DiaMedica Therapeutics seller in Q2 2025 was Susquehanna International Group, an estimated $2.04M sold.
Based on aggregated 13F filings for Q2 2025.